Fusion Antibodies presents at the Proactive One2One Investor Conference - Adrian Kinkaid, CEO, Fusion Antibodies PLC 00:00:00
Fusion Antibodies PLC, CEO Adrian Kinkaid presented at the Proactive One2One Investor Conference. The company is diversifying its focus from primarily therapeutics to include diagnostics and research applications of antibodies. Kinkaid emphasised the company's expertise in antibody discovery, engineering, and manufacturing, highlighting its ability to reduce production costs and enhance efficiency.